Incidence of COVID-19 in Patients With Chronic Idiopathic Urticaria and Asthma on Omalizumab: A Multicentre Retrospective Cohort Study

Abstract

Keywords

SARS-CoV-2 COVID-19 omalizumab dermatology asthma urticaria

Get full access to this article

View all access options for this article.

References

Cruz

AA.

Lima

Sarinho

et al. Safety of anti-immunoglobulin E therapy with omalizumab in allergic patients at risk of geohelminth infection. Clin Exp Allergy. 2007;37(2):197-207.doi:10.1111/j.1365-2222.2007.02650.x

17250692

Covid-19 Data and spread Ontario . Accessed April 30, 2021. https://covid-19.ontario.ca/data#effective-reproductionca

Romero-Severson

Sanche

Hengartner

. Estimating the reproductive number R₀ of SARS-CoV-2 in the United States and eight European countries and implications for vaccination. J Theor Biol. 2021;517:110621. doi:10.1016/j.jtbi.2021.110621

33587929

Farmani

AR.

Mahdavinezhad

Moslemi

et al. Anti-IgE monoclonal antibodies as potential treatment in COVID-19. Immunopharmacol Immunotoxicol. 2021;43(3):259-264.doi:10.1080/08923973.2021.1925906

34018464

Hanon

Brusselle

Deschampheleire

et al. COVID-19 and biologics in severe asthma: data from the Belgian Severe Asthma Registry [published online ahead of print, 2020 Oct 22]. Eur Respir J. 2020;56(6):2002857. doi:10.1183/13993003.02857-2020